These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2587840)

  • 21. Computer-automated structure evaluation of flavonoids and other structurally related compounds as glyoxalase I enzyme inhibitors.
    Klopman G; Dimayuga ML
    Mol Pharmacol; 1988 Aug; 34(2):218-22. PubMed ID: 3412324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of glyoxalase I in vitro.
    Brandt RB; Brandt ME; April ME; Thomson C
    Biochem Med; 1983 Jun; 29(3):385-91. PubMed ID: 6615496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Squaric acid N-hydroxylamides: synthesis, structure, and properties of vinylogous hydroxamic acid analogues.
    Lim NC; Morton MD; Jenkins HA; Brückner C
    J Org Chem; 2003 Nov; 68(24):9233-41. PubMed ID: 14629141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of alpha-hydroxythiol esters as antitumor agents and glyoxalase I inhibitors.
    Hall SS; Doweyko LM; Doweyko AM; Zilenovski JS
    J Med Chem; 1977 Oct; 20(10):1239-42. PubMed ID: 903914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and study of glutaryl-S-(omega-aminoalkyl)-L-cysteinylglycines as inhibitors of glyoxalase I.
    Phillips GW; Norton SJ
    J Med Chem; 1975 May; 18(5):482-6. PubMed ID: 1171239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotactic peptide-induced arachidonic acid mobilization in human polymorphonuclear leukocytes.
    Galbraith GM
    Am J Pathol; 1988 Nov; 133(2):347-54. PubMed ID: 3142268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New chemotactic dimeric peptides show high affinity and potency at the human formylpeptide receptor.
    Spisani S; Fraulini A; Varani K; Falzarano S; Cavicchioni G
    Eur J Pharmacol; 2007 Jul; 567(1-2):171-6. PubMed ID: 17481605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclobutane dimers of 1-methylthymine: isolation, identification and properties.
    Stepień E; Lisewski R; Wierzchowski KL
    Acta Biochim Pol; 1973; 20(3):297-311. PubMed ID: 4749668
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of low doses of lead and cadmium on glyoxalase I and glyoxalase II activities of the liver and brain of rats].
    Winter R; Piskorska D
    Med Pr; 1984; 35(3):177-83. PubMed ID: 6503685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of porphyrogenic drugs on the glyoxalase enzymes.
    Van Brummelen R; Myburgh S; Bissbort SH
    Res Commun Chem Pathol Pharmacol; 1993 Dec; 82(3):339-49. PubMed ID: 8122034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Activity of glyoxalase and glyoxalase II under the effect of toxohormone from melanoma].
    Winter R; Piskorska D; Jerzykowski T; Grabowska AM
    Patol Pol; 1980; 31(1):35-40. PubMed ID: 7190262
    [No Abstract]   [Full Text] [Related]  

  • 32. A new class of semisynthetic anthracycline glycoside antibiotics incorporating a squaric acid moiety.
    Sztaricskai F; Sum A; Roth E; Pelyvás IF; Sándor S; Batta G; Herczegh P; Reményi J; Miklán Z; Hudecz F
    J Antibiot (Tokyo); 2005 Nov; 58(11):704-14. PubMed ID: 16466024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. pH Dependence of the inhibition of yeast glyoxalase I by porphyrins.
    Douglas KT; Sharif JG
    Biochim Biophys Acta; 1983 Oct; 748(2):184-93. PubMed ID: 6354270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I.
    More SS; Vince R
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6039-42. PubMed ID: 16997560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and activity of gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycine: a metabolically stable inhibitor of glyoxalase I.
    Vince R; Brownell J; Akella LB
    Bioorg Med Chem Lett; 1999 Mar; 9(6):853-6. PubMed ID: 10206549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, structure and biological properties of aflatoxin B1 aldehyde.
    Osiyemi FO; Adekunle AA
    Acta Pharm Suec; 1973 Dec; 10(6):526-8. PubMed ID: 4773120
    [No Abstract]   [Full Text] [Related]  

  • 37. The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
    Doweyko AM
    J Med Chem; 1988 Jul; 31(7):1396-406. PubMed ID: 3290487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoro-modified chemotactic peptides: fMLF analogues.
    Koksch B; Dahl C; Radics G; Vocks A; Arnold K; Arnhold J; Sieler J; Burger K
    J Pept Sci; 2004 Feb; 10(2):67-81. PubMed ID: 14994985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structures and spectroscopic properties of ester amide and diamide of squaric acid with prolinamide.
    Kolev T; Seidel RW; Mayer-Figge H; Spiteller M; Sheldrick WS; Koleva BB
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Apr; 72(3):502-9. PubMed ID: 19101193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glyoxalase enzyme system (author's transl)].
    Winter R; Piskorska D
    Postepy Biochem; 1980; 26(3):389-409. PubMed ID: 6782560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.